Current status of anti-HBV chemotherapy

Archives of Pharmacal Research

Volumn 21, Issue 2, 1998, Pages 89-105

  Hong, Joon H ^a   Choi, Yongseok ^a   Chun, Byoung K ^a   Lee, Kyeong ^a   Chu, Chung K ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

3TC; Chemotherapy; Famciclovir; Hepatitis B virus; Immunomodulationg agents; Nucleoside analogues; Resistance

Indexed keywords

ANTIVIRUS AGENT;

ANIMAL; DRUG EFFECT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; REVIEW; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; HEPATITIS B; HEPATITIS B VIRUS; HUMANS;

EID: 0032035173     PISSN: 02536269     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02974012     Document Type: Review

References (128)

1. Abbruzzese, J. L., Schmidt, S., Raber, M. N., Levy, J. K., Castellanos, A. M., Legha, S. S. and Krakoff, I. H., Phase I trial of 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU) terminated by severe neurologic toxicity. Invest. New Drugs, 7, 195-201 (1989).
2. Acs, G., Sells, M. A., Purcell, R. H., Price, P., Engle, R., Shapiro, M. and Popper, H., Hepatitis B virus produced by transfected Hep G2 cells causes hepatitis in chimpanzees. Proc. Natl. Acad. Sci. USA, 84, 4641-4644 (1987).
3. Ashwell, G. and Harford, J., Carbohydrate-specific receptors of the liver. Ann. Rev. Biochem., 51, 531-534 (1982).
4. Bartholomew, M. M., Jansen, R. W., Jeffers, L. J., Reddy, K. R., Johnson, L. C., Bunzendahl, H., Condreay, L. D., Tzakis, A. G., Schiff, E. R. and Brown, N. A., hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349, 20-22 (1997).
5. Beach, J. W., Jeong, L. S., Alves, A. J., Pohl, D., Kim, H. O., Chang, C.-H., Doong, S.-L., Schinazi, R. F., Cheng, Y.-C. and Chu, C. K., Synthesis of enantiomerically pure (2′R, 5′S)-(-)-1-(2-hydroxymethyloxathiolan-5-yl)cytosine as a potent antiviral agent against hepatitis B virus (HBV) and human immunodeficiency virus (HIV). J. Org. Chem., 57, 2217-2219 (1992).
6. Belleau, B., Dixit, D., Nguyen-Ga, N. and Kraus, J.-L., International Conference on AIDS. Montreal, Canada, June 4-9, paper no. T.C.O.1. (1990).
7. Benhamou, Y., Dohin, E. and Lunel-Fabiani, F., Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet, 345, 396-397 (1995).
8. Berk, L., Schalm, S. W., De Man, R. A., Heijtink, R. A., Berthelot, P., Brechot, C., Boboc, B., Degos, F., Maecelling, P., Behamou, J.-P., Hess, G., Rossol, S., Meyer, B. M., Berlinger, C., Stalder, G. A., Den Ouden-Muller, J. W. and De Jong, M., Failure of acyclovir to enhance the antiviral effect of alpha lymphoblastoid interferon on HBeAg-seroconversion in chronic hepatitis B: a multi-center randomized controlled trial. J. Hepatol., 14, 305-309 (1992).
9. Bisacchi, G. S., Chao, S. T., Bachard, C., daris, J. P., Innaimo, S., Jacobs, G. A., Kocy, O., Lapointe, P., Martel, A., Merchant, Z., Slusarchyk, W. A., Sundeen, J. E., Youg, M. G., Colonno, R. and Zahler, R., BMS-200475, a novel carbocyclic 2′-deoxyguanosine analogue with potent and selective anti-hepatitis B virus activity in vitro. Bioorg. Med. Chem. Lett., 7, 127-132 (1997).
10. Bruch, H. R., Korn, A., Klein, H., Markus, R., Malmus, K., Baumgarten, R. and Muller, R., Treatment of chronic hepatitis B with interferon alpha-2b and interleukin-2. J. Hepatol., 17, S52-S55 (1993).
11. Chen, C.-H., Vazquez-Padua, M. and Cheng, Y.-C. Effect of anti-huamn immunodeficiency virus nucleoside analogues on mitochondrial DNA and its implication for delayed toxicity. Molecular Pharmacol., 39, 625-628 (1991).
12. Cheng, Y. C., Huang, E.S., Lin, J. C., Mar, E. C., Pagano, J. S., Dutschman, G. E. and Grill, S. P., Unique spectrum of activity of 9-(1,3-dihydroxy-2-propoxymethyl) guanine against herpes viruses in vitro and its mode of action against herpes simplex virus type 1. Proc. Natl. Acad. Sci. USA, 80, 2767-2770 (1983).
13. Chien, R. N. and Liaw, Y. F., Drug therapy in patients with chronic type B hepatitis. J. Formos. Med. Assoc., 94, suppl. 1, S1-S9 (1995).
14. Chu, C. K., Ahn, S. K., Kim, H. O., Beach, J. W., Alves, A. J., Jeong, L. S., Islam, Q., Van Roey, P. and Schinazi, R. F., Asymmetric synthesis of enantiomerically pure (-)-β-D-dioxolane-thymine and its anti-HIV activity. Tetrahedron Lett., 32, 3791-3794 (1991).
15. Chu, C. K., Ma, T. W., Shanmuganathan, K., Wang, C.-G., Xiang, Y.-J., Pai, S. B., Yao, G.-Q., Sommadossi, J.-P. and Cheng, Y.-C., Use of 2′-fluoro-5-methyl-β-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob. Agents Chemother., 39 979-981 (1995).
16. Civitico, G., Shaw, T. and Locarnini, S. Interaction between ganciclovir and foscarnet as inhibitors of duck hepatitis B virus replication in vitro. Antimicrob. Agents Chemother., 40, 1180-1185 (1996).
17. Clark, J. M., Genovesi, E. V., Medina, I., Lamb, L., Taylor, D., Standring, D., Seifer, M., Innaimo, S. and Collono, R. J. Maintenance therapy with BMS-200475 in the woodchuck model of chronic hepatitis B infection. Abstracts of 37th ICAAC. Canada, September 28-October 1, pp 215 (1997).
18. Colonno, R. J., Innaimo, S. F., Seifer, M., Genovesi, E., Clark, J., Yamanaka, R., Hamatake, B., Terry, B., Standring, D., Bisacchi, G., Sundeen, J. and Zahler, R., Identification of BMS-200475 as a novel and potent inhibitor of hepatitis B virus replication. Abstracts of Conf. on Antiviral Res. Atlanta, 34, A51, 32 (1997).
19. Cui, L., Schinazi, R. F., Gosselin, G., Imbach, J.-L., Chu, C. K., Rando, R. F., Revankar, G. R. and Sommadossi, J.-P., Effect of β-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Biochem. Pharmacol., 52, 1577-1584 (1996).
20. Cui, L., Yoon, S., Schinazi, R. F. and Sommadossi, J.-P., Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-β-D-arabinofuranosyl)-5-iodouracil in human liver cells. J. Clin. Invest., 95, 555-563 (1995).
21. De Clercq, E., Sakuma, T., Baba, M., Pauwels, R., Balzarini, J., Rosenberg, I. and Holy, A., Antiviral activity of phosphylmethoxyalkyl derivatives of purines and pyrimidines. Antiviral Res., 8, 261-272 (1987).
22. Dienstag, J. L., Perrillo, R. P., Schiff, E. R., Bartholomew, M., Vicary, C. and Rubin, M., A preliminary trial of lamivudine for chronic hepatitis B infection. New Engl. J. Med., 333, 1657-1661 (1995).
23. Doong, S.-L., Tsai, C. H., Schinazi, R. F., Liotta, D. C. and Cheng, Y.-C., Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc. Natl. Acad. Sci. USA., 88, 8495-8499 (1991).
24. Dusheiko, G. M., Treatment and prevention of chronic viral hepatitis. Pharmacol. Ther., 65, 47-73 (1995).
25. Fisher, K. P. and Tyrrell, D. L. J., Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine (-)-β-L-2′,3′-dideoxy-3′-thiacytidine in vitro. Antimicrob. Agents Chemother., 40, 1957-1960 (1996).
26. Fiume, L., Busi, C., Mattioli, A., Balboni, P. G. and Barbanti-Brodano, G., Hepatocyte targeting of adenine-9-β-D-arabinofuranoside 5′-monophosphate (ara-AMP) coupled to lactosaminated albumin. FEBS Lett., 129, 261-264 (1981).
27. Fiume, L., Di Stefano, G., Busi, C., Mattioli, A., Rapicetta, M., Giuseppetti, R., Ciccaglione, A. and Argentini, C., Inhibition of woodchuck hepatitis virus replication by adenine arabinoside monophosphate coupled to lactosaminated poly-L-lysine and administered by intramuscular route. Hepatology, 22, 1072-1077 (1995).
28. Fourel, I., Cullen, J., Saputelli, J., Aldrich, C., Schaffer, P., Averett, D., Pugh, J. and Mason, W., Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks. J. Virol., 68, 8321-8330 (1994).
29. Fourel, I., Hantz, O., Watanabe, K. A., Jacquet, C., Chomel, B., Fox, J. and Trepo, C., Inhibitory effects of 2′-fluoro arabinosyl-pyrimidine nucleosides on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob. Agents Chemother., 34, 473-475 (1990).
30. Fourel, I., Li, J., Hantz, O., Jacquet, C., Fox, J. J. and Trepo, C., Effects of 2′-fluorinated arabinosyl-pyrimidine nucleosides on duck hepatitis B virus DNA level in serum and liver of chronically infected ducks. J. Med. Virol. 37, 122-126 (1992).
31. Fourel, I., Saputelli, J., Schaffer, P. and Mason, W. S., The carbocyclic analogue of 2′-deoxyguanosine induces a prolonged inhibition of duck hepatitis B virus DNA synthesis in primary hepatocyte cultures and in the liver. J. Virol., 68, 1059-1065 (1994).
32. Fridland, A., Robbins, B. L. and Srinivas, R. V., Antiretroviral activity and metabolism of bis(POC)PMPA, an oral bioavailable prodrug of PMPA. Antiviral Res., 34, A49 (1997).
33. Fried, M. W., Di Bisceglie, A. M., Straus, S. E., Savarese, B., Beames, M. P. and Hoofnagle, J. H., Hepatology, 16, 127A (1992).
34. Fried, M. W., Fong, T.-L., Swain, M. G., Park, Y., Beames, M. P., Banks, S. M., Hoofnagle, J. H. and Di Bisceglie, A. M., Therapy of chronic hepatitis B with a 6-month course of ribavirin. J. Hepatol., 21, 145-150 (1994).
35. Fried, M. W., Korenman, J. C., Di Bisceglie, A. M., Park, Y., Waggoner, J. G., Mitsuya, H., Hartman, N. R., Yarchoan, R., Broder, S. and Hoofnagle, J. H., A pilot study of 2′,3′-dideoxyinosine for the treatment of chronic hepatitis B. Hepatology, 16, 861-864 (1992).
36. Furman, P. A., Davis, M., Liotta, D. C., Paff, M., Frick, L. W., Nelson, D. J., Dornsife, R. E., Wurster, J. A., Wilson, L. J., Fyfe, J. A., Tuttle, J. V., Miller, W. H., Condreay, L., Averette, D. R., Schinazi, R. F. and Painter, G. R., The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob. Agents Chemother., 36, 2686-2692 (1992).
37. Gish, R. G., Lau, J. Y., Brooks, L., Fang, J. W., Steady, S. L., Imperial, J. C., Garcia, K. R., Esquivel, C. O. and Keeffe, E. B., Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology, 23, 1-7 (1996).
38. Gosselin, G., Schinazi, R. F., Sommadossi, J.-P., Mathe, C., Bergogne, M.-C., Aubertin, A.-M., Kirn, A. and Imbach, J.-L., Anti-human immunodeficiency virus activities of the β-L-enantiomer of 2′,3′-dideoxycytidine and its 5-fluoro derivative in vitro. Antimicrob. Agents Chemother., 38, 1292-1297 (1994).
39. Grove, K. L., Guo, X., Liu, S.-H., Gao, Z., Chu, C. K. and Cheng, Y.-C., Anticancer activity of β-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L-configuration. Cancer Res., 55, 3008-3011 (1995).
40. Guidotti, L. G., Guilhot, S. and Chisari, F. V., Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and independent pathways. J. Virol., 68, 1265-1270 (1994).
41. Hantz, O., Allaudeen, H. S., Ooka, T., De Clerq, E. and Trepo, C., Inhibition of human and woodchuck hepatitis virus DNA polymerase by the triphosphates of acyclovir, 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-iodocytosine and E-5-(2-bromovinyl)-2′-deoxyuridine. Antiviral Res., 4, 187-199 (1984).
42. Hantz, O., Borel, C., Trabaud, C., Zoulim, F., Dessolin, J., Camplo, M., Vlieghe, P., Bouygues, M., Trepo, Christian. and Kraus, J. L., Selective inhibition of the duck hepatitis B virus by a new class tetraazamacrocycles. Antimicrob. Agents Chemother. 41, 2579-2581 (1997).
43. Heijtink, R. A., De Wilde, G. A., Kruining, J., Berk, L., Balzarini, J., De Clerq, E., Holy, A. and Schalm, S. W., Inhibitory effect of 9-(2-phosphanylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res., 21, 141-153 (1993).
44. Helgstrand, E., Eriksson, B., Johansson, N. G., Lannero, B., Larsson, A., Misiorny, A., Noren, J. O., Sjoberg, B., Stenberg, K., Stening, G., Stridh, S., Oberg, B., Alenius, S. and Philipson, L., Trisodium phosphonoformate, a new antiviral compound. Science, 201, 819-821 (1978).
45. Hitchcock, M. J. M., Jaffe, H. S., Martin, J. C. and Stagg, R. J., Cidofovir-a new agent with potent anti-herpesvirus activity. Antiviral Chem. Chemother., 7, 115-127 (1996).
46. Hoofnagle, J. H., Hanson, R. G., Minuk, G. Y., Pappas, S. C., Schafer, D. F., Dusheiko, G. M., Straus, S. E., Popper, H. and Jones, E. A., Randomized controlled trial of adenine arabinoside monophosphate for chronic type B hepatitis. Gastroenterology, 86, 150-157 (1984).
47. Isley, D. D., Lee, S.-H., Miller, W. H. and Kutchta, R. D., Acyclic guanosine analogs inhibit DNA polymerase α, β and ε with very different potencies and have unique mechanisms of action. Biochemistry, 34, 2504-2510 (1995).
48. Jacyna, M. R. and Thomas, H. C., Antiviral therapy: hepatitis B. Br. Med. Bull., 46, 368-382 (1990).
49. Jansen, R. W., Johnson, L. C. and Averett, D. R., High-capacity in vitro assessment of anti-hepatitis B virus compound selectivity by a virion-specific polymerase chain reaction assay. Antimicrob. Agents Chemother., 37, 441-447 (1993).
50. Kim, H. O., Schinazi, R. F., Shanmuganathan, K., Jeong, L. S., Beach, J. W., Nampalli, S., Cannon, D. L. and Chu, C. K., L-β-(2S, 4S)- and L-β-(2S, 4R)-Dioxolanyl nucleosides as potential anti-HIV agents: asymmetric synthesis and structure-activity relationships. J. Med. Chem., 36, 519-528 (1993).
51. Kim, H. O., Shanmuganathan, K., Alves, A. J., Jeong, L. S., Beach, J. W., Schinazi, R. F., Chang, C.-N., Cheng, Y.-C. and Chu, C. K., Potent anti-HIV and anti-HBV activities of (-)-L-β-dioxolane-C and (+)-L-β-dioxolane-T and their asymmetric synthesis. Tetrahedron Lett., 33, 6899-6902 (1992).
52. Kitos, T. E., Huang, J. S., Tovell, D. and Tyrrell, D. L. J., A comparison of drug metabolism and anti-hepadnavirus activity in two in vitro cell culture test systems. Abstracts, Paris, France (1991).
53. Korba, B. E. and Gerin, J. L., Antisense oligonucleotides are effective inhibitors of hepatitis B virus replication in vitro. Antiviral Res., 28, 225-242 (1995).
54. Korba, B. E. and Milman, G., A cell culture assay for compounds which inhibit hepatitis B virus replication. Antiviral Res., 15, 217-228 (1991).
55. Korba, B. E., Baldwin, B., Cote, P., Schinazi, R., Gangemi, D., Gerin, J. L. and Tennant, B. C., Efectiveness of combination therapies with 3TC, famciclovir and alpha interferon against woodchuk hepatitis virus replication in chronically infected woodchuck: modelfor potential anti-HBV treatments. Abstracts of 37th ICAAC. Canada, September 28-October 1, pp.219 (1997).
56. Korba, B. E. and Boyd, M. R., Penciclovir is an effective inhibitor of hepatitis B virus replicator in vitro. Antimicrob. Agents Chemother., 40, 1282-1284 (1996).
57. Korenman, J., Baker, B., Waggoner, J., Everhart, J. E., Di Bisceglie, A. M. and Hoofnagle, J. H., Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann. Int. Med., 114, 629-634 (1991).
58. Kreis, W., Damin, L., Colacino, J., Lopez, C. In vitro metabolism of 1-β-D-arabinofuranosylcytosine and 1-β-D-2′-fluoroarabino-5-iodocytosine in normal and herpes simplex type 1 infected cells. Biochem. Pharm., 31, 767-773 (1982).
59. Kruining, J., Heijtink, R. A. and Schalm, S. W. Antiviral agents in hepatitis B virus transfected cell lines: inhibitory and cytotoxic effect related to time and treatment. J. Hepatol., 22, 263-267 (1995).
60. Lee, B., Luo, W. X., Suzuki, S., Robins, M. J. and Tyrrell, D. L., In vitro and in vivo comparison of the abilities of purine and pyrimidine 2′,3′-dideoxynucleosides to inhibit duck hepadnavirus. Antimicrob. Agents Chemother., 33, 336-339 (1989).
61. Lin, T. S., Luo, M. Z., Pai, S. B., Dutschuman, G. E. and Cheng, Y.-C., Synthesis and biological evaluation of 2′,3′-dideoxy-L-pyrimidine nucleosides as potential antiviral agents against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). J. Med. Chem., 37, 798-803 (1994).
62. Lin, T. S., Luo, M.-Z., Liu, M.-C., Zhu, Y.-L., Gullen, E., Dutschman, G. E. and Cheng, Y.-C., Design and synthesis of 2′,3′-dideoxy-2′,3′-didehydro-β-L-cytidine (β-L-d4C) and of 2′,3′-dideoxy-2′,3′-didehydro-β-L-5-fluorocytidine (β-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro. J. Med. Chem., 39, 1757-1759 (1996).
63. Ling, R., Mutimer, D., Ahmed, M., Boxall, E. H., Elias, E., Dusheiko, G, M. and Harrison, T. J., Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology, 24, 711-713 (1996).
64. Lopez, C., Watanabe, K. A. and Fox, J. J., 2′-Fluoro-5-iodoaracytosine, a potent and selective anti-herpesvirus agent. Antimicrob. Agents Chemother., 17, 803-806 (1980).
65. Luscombe, C., Pedersen, J., Uren, E. and Locarnini, S., Long-term ganciclovir chemotherapy for congenital duck hepatitis B virus infection in vivo: effect on intrahepatic-viral DNA, RNA, and protein expression. Hepatology, 24, 766-773 (1996).
66. Macilwain, C., NIH, FDA seek lessons from the hepatitis B drug trial deaths. Nature, 364, 275-275 (1993).
67. Marques, A. R., Lau, D., Mckenzie, R., Strus, S. and Hoofnagle, J., Combination therapy with famciclovir and interferon for the treatment of chronic hepatitis B. Abstracts of 37th ICAAC. Canada, September 28-October 1, pp 219 (1997).
68. Martin, J. C., Dvorak, C. A., Smee, D. F., Matthews, T. R. and Verheyden, J. P. H., 9-(1,3-dihydroxy-2-propoxymethyl)guanine: a new potent and selective antiherpes agent. J. Med. Chem., 26, 759-761 (1983).
69. Martin, P., Kassianides, C., Hoofnagle, J. H., Mitsuya, H. and Border, S., Effects of 2′,3′-dideoxyadenosine on duck hepatitis B virus. Hepatology, 8, A1329 (1988).
70. Matthes, E., Von Janta-Iipinski, M., Will, H., Schroder, H. C., Merz, H., Steffen, R. and Muller, W. E. G., Inhibition of hepatitis B virus production by modified 2′,3′-dideoxy-thymidine and 2′,3′-dideoxy-5-methyl-cytidine derivatives in vitro and in vivo studies. Biochem. Pharmacol., 43, 1571-1577 (1992).
71. Miller, R. H., Kaneko, S., Chung, C. T., Girones, R. and Purcell, R. H., Compact organization of the hepatitis B virus genome. Hepatology, 9, 322-327 (1989).
72. Minuk, G. Y., German, G. B., Bernstein, C., Benarroch, A., Gauthier, T. and Sekla, L., A pilot study of steroid withdrawal followed by oral acyclovir in the treatment of chronic type B hepatitis. Clin. Invest. Med., 15, 506-512 (1992).
73. Mutchnick, M. G., Appelman, H. D., Chung, H. T., Aragona, E., Gupta, T. P., Cummings, G. D., Waggoner, J. G., Hoofnagle, J. H. and Shafritz, D. A., Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology, 14, 409-415 (1991).
74. Nicoll, A. J., Colledge, D. L., Wang, Y. Y., Toole, J. J., Dean, J. K., Angus, P. W., Smallwood, R. A. and Locarnini, S. A., PMEA, an acyclic phosphonate nucleoside analogue with activity against duck hepatitis B virus in vivo. Hepatology, 220A, 375 (1996).
75. Norbeck, D. W., Spanton, S., Broder, S. and Mitsuya, H., (±)-Dioxolane-T {(±)-1-[(2β,4β)-2-(hydroxymethyl4-dioxolanyl]thymine}. A new 2′,3′-dideoxy nucleoside prototype with in vitro activity against HIV. Tetrahedron Lett., 30, 6263-6266 (1989).
76. Offensperger, W. B., Blum, H. E. and Gerok, W., Molecular therapeutic strategies in hepatitis B virus infection. Clin. Invest. 72, 737-741 (1994).
77. Pai, S. B., Liu, S.-H., Zhu, Y.-L., Chu, C. K. and Cheng, Y.-C., Inhibition of hepatitis B virus by a novel L-nucleoside, 2′-fluoro-5-methyl-β-L-arabinofuranosyl uridine. Antimicrob. Agents and Chemother., 40 380-386 (1996).
78. Parker, W. B. and Cheng, Y.-C., Disruption of energy metabolism and mitochondrial function. In Neurotoxicology: Approaches and Methods. pp. 483-490. Ed. Academic Press, Inc. 1995.
79. Parker, W. B. and Cheng, Y.-C., Mitochondrial toxicity of antiviral nucleoside analogues. J. NIH Res., 6, 57-61 (1994).
80. Peek, S. F., Jacob, J. R., Tochkov, I. A., Kobra, B. E., Gerin, J. L., Chu, C. K. and Tennant, B. C., Sustained antiviral activity of 1-(2-fluoro-methyl-β-L-arabinofuranosyl)uracil (L-FMAU) in the woodchuck model of hepatitis B virus (HBV) infection. Abstracts of 37th ICAAC. Canada, September 28-October 1, pp. 215 (1997).
81. Perry, C. M. and Wagstaff, A. J., Famciclovir: a review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Drugs, 50, 396-415 (1995).
82. Ponzetto, A., Fiume, L., Forzani, B., Song, S. Y., Busi, C., Mattioli, A., Spinelli, M., Smedile, A., Chiaberge, E., Bonino, F., Gervasi, G. B., Rapicetta, M. and Verme, G., Adenine arabinoside monophosphate and acyclovir monophosphate coupled to lactosaminated albumin reduce woodchuck hepatitis virus viremia at doses lower than do the unconjugated drugs. Hepatology, 14, 16-24 (1991).
83. Price, P. M., Banerjee, R. and Acs, G., Inhibition of the replication of hepatitis B virus by the carbocyclic analogue of 2′-deoxyguanosine. Proc. Natl. Acad. Sci. USA, 86, 8541-8544 (1989).
84. Price, P. M., Banerjee, R., Jeffrey, A. M. and Acs, G., The mechanism of inhibition of hepatitis B virus replication by the carbocyclic analogue of 2′-deoxyguanosine. Hepatology, 16, 8-12 (1992).
85. Purcell, R. H. and Gerin, J. L., Hepatitis B vaccines on the threshold. Am. J. Clin. Pathol., 70, 159-169 (1978).
86. Rajagopalan, P. F., Boudinot, F. D., Chu, C. K., McClure, H. M. and Schinazi, R. F., Pharmacokinetics of (-)-β-D-2,6-diaminopurine dioxolane and its metabolite dioxolane guanosine in rhesus monkeys. Pharm. Res., 11, suppl. 381 (1994).
87. Rajagopalan, P., Boudinot, F. D., Chu, C. K., Tennant, B. C., Baldwin, B. H. and Schinazi, R. F., Pharmacokinetics of (-)-β-D-2,6-diaminopurine dioxolane and its metabolite, dioxolane guanosine, in woodchucks (Marmota monax). Antiviral Chem. Chemother., 7, 65-70 (1996).
88. Ryff, J. C., To treat or not to treat? The judicious use of interferon-α-2a for the treatment of chronic hepatitis B virus. J. Hepatology., 17, suppl. 3, S42-S46 (1993).
89. Schalm, S. W., Heijitink, R. A., Van Buuren, H. R. and De Man, R. A., Acyclovir, oral, intravenous and combined with interferon for chronic HBeAg-positive hepatitis. J. Hepatol., 3, suppl. 2, S137-S 141 (1986).
90. Schalm, S. W., Heijitink, R. A., Van Buuren, H. R. and De Man, R. A., Lymphoblastoid alpha-interferon, weekly, daily and combined with acyclovir for chronic HBeAg-positive hepatitis. J. Hepatol., 3, suppl. 2, S189-S192 (1986).
91. Schinazi, R. F., McClure, H. M., Boudinout, F. D., Xiang, Y.-J. and Chu, C. K., Development of (-)-β-D-2, 6-diaminopurine dioxolane as a potential antiviral agent. Antiviral Res., 23, suppl. 81 (1994).
92. Schinazi, R. F., McMillan, A., Cannon, D., Mathis, R., Lloyd, R. M., Peck, A., Sommadossi, J.-P., St Clair, M., Wilson, J., Furman, P. A., Painter, G., Choi, W. B. and Liotta, D.C., Selective inhibition of human immunodeficiency viruses by racemates and enatiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob. Agents Chemother., 36, 2423-2431 (1992).
93. Sells, M. A., Chen, M.-L. and Acs, G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc. Natl. Acad. Sci. USA, 84, 1005-1009 (1987).
94. Sells, M. A., Zelent, A. Z., Shvartsman, M. and Acs, G., Replicative intermediate of hepatitis B virus in HepG2 cells that produce infectious virions. J. Virol., 62, 2836-2844 (1988).
95. Severini, A., Liu, X.-Y., Wilson, J. S. and Tyrrell, D. L. J., Mechanism of inhibiton of duck hepatitis B virus polymerase by (-)-β-L-2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother., 39, 1430-1435 (1995).
96. Shaw, T., Amor, P., Civitico, G., Boyd, M. and Locarnini, S., In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob. Agents Chemother., 38, 719-723 (1994).
97. Sheron, N., Lau, J. Y., Daniels, H. M., Webster, J., Eddleston, A. L., Alexander, G. J. and Williams, R., Tumor necrosis factor to treat chronic hepatitis B virus infection. Lancet, 336, 321-322 (1990).
98. Sidewell, R. W., Huffman, J. H., Khare, G. P., Allen, L. B., Witkowski, J. T. and Robins, R. K., Broad-spectrum antiviral activity of virazole: 1-β-D-ribofuranosyl-1,2,4-tiazole-3-carboxamide. Science, 177, 705-706 (1972).
99. Sidewell, R. W., Revankar, G. R. and Robin, R. K., Ribavirin: review of a broad-spectrum antiviral agent. In Viral Chemotherapy Vol. 2. Ed. by D. Shugar., pp.49-108. Oxford: Pergamon Press (1985).
100. Smith, K. O., Galloway, K. S., Kennell, W. L., Ogilvie, K. K. and Radatus, B. K., A new nucleoside analogue, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, highly active in vitro against herpes simplex virus types 1 and 2. Antimicrob. Agents Chemother., 22, 55-61 (1982).
101. Soudeyns, H., Yao, Q., Belleau, B., Kraus, J.-L., Nguyen-Ga, N., Spira, B. and Wainberg, M. A., Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocyclic nucleoside analogue. Antimicrob. Agents Chemother., 35, 1386-1390 (1991).
102. Spector, S. A., McKinley, G. S., Lalezari, J. P., Samo, T., Andruczk, R., Follansbee, S., Sparti, P. D., Havlir, D. V., Simpson, G., Buhles, W. Wong, R. and Stempien, M. J., Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. New. Engl. J. Med., 334, 1491-1497 (1996).
103. Starnes, M. C. and Cheng, Y.-C., Cellular metabolism of 2′,3′-dideoxycytidine, a compound active against human immunodeficiency virus in vitro. J. Biol. Chem., 262, 988 (1987).
104. Sureau, C., Romet-Lemonne, J. L., Mullins, J. I. and Essex, M., Production of hepatitis B virus by a differentiated human hepatoma cell line after transfection with cloned circular HBV DNA. Cell, 47, 37-47 (1986).
105. Tennant, B., Jacob, J., Graham, L. A., Peek, S., Du, J. and Chu, C. K., Pharmacokinetic and pharmacodynamic studies of 1-(2-fluoro-5-methyl-β-L-arabinofuranosyl)uracil (L-FMAU) in the woodchuck model of hepatitis B virus (HBV) infection. Antiviral Res., 34, A52, 36 (1997).
106. Tenney, D. J., Yamanaka, G., Voss, S. M., Cianci, C. W., Tuomari, A. V., Sheaffer, A. K., Alam, M. and Colonno, R. J., Lobucavir is phosphorlated in human cytomegalovirus-infected and uninfected cell and inhibitis the viral DNA polymerase. Antimicrob. Agents Chemother., 41, 2680-2685 (1997).
107. Thymosin alpha 1 shows efficacy for hepatitis B. Antiviral Agents Bull., 9, 194-195 (1996).
108. Tiollais, P., Pourcel, C. and Dejean, A., The hepatitis B virus. Nature, 317, 489-495 (1985).
109. Tipples, G. A., Ma, M. M., Fisher, K. P., Bain, V. G., Kneteman, N. M. and Tyrrell, D. J. L., Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology, 24, 714-717 (1996).
110. Touchette, N., HBV-drug deaths prompt restudy of similar antivirals. J. NIH Res., 5, 33-36 (1993).
111. Tsiquaye, K., Slomka, M. J. and Maung, M., Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in vivo. J. Med. Virol., 42, 306-310 (1994).
112. Tsurimoto, T., Fujiyama, A. and Matsubara, K., Stable expression and replication of hepatitis B virus genome in an integrated state in a human hepatoblastoma cell line transfected with the cloned viral DNA. Proc. Natl. Acad. Sci. USA, 84, 444-448 (1987).
113. Tuttleman, J. S., Pugh, J. C. and Summers, J. W., In vitro experimental infection of primary duck hepatocyte cultures with duck hepatitis B virus. J. Virol., 58, 17-25 (1986).
114. Tyrrell, D. L. J., Fisher, K., Savani, K., Ian, W. and Jewell, L., Treatment of chimpanzees and ducks with lamivudine, 2′,3′-dideoxy-3′-thiacytidine results in a rapid suppression of hepadnaviral DNA in sera. Clin. Invest. Med., 16, Suppl. 4, B77. Abstract (1993).
115. Vere Hodge, R. A. and Cheng, Y. C., The mode of action of penciclovir. Antiviral Chem. Chemother., 4, 13-24 (1993).
116. Wagstaff, A. J. and Bryson, H. M., Foscarnet, a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs, 48, 199-226 (1994).
117. Watanabe, K. A., Reichman, U., Hirota, K., Lopez, C. and Fox, J. J.. Nucleosides. 110. Synthesis and antiherpes virus activity of some 2′-fluoro-2′-deoxy-arabinofuranosylpyrimidine nucleosides. J. Med. Chem., 22, 21-24 (1979).
118. Watanabe, K. A., Su, T.-L., Klein, R. S., Chu, C. K., Matsuda, A., Chun, M. W., Lopez, C. and Fox, J. J., Nucleosides. 123. Synthesis of antiviral nucleosides, 5-substituted 1-(2-deoxy-2-halogeno-β-D-arabinofuranosyl) cytosines and uracils, some structure-activity relationships. J. Med. Chem., 26, 152-156 (1983).
119. Watanabe, K. A., Su, T.-L., Reichman, U., Greenberg, N., Lopez, C. and Fox, J. J., Nucleosides. 129. Synthesis of antiviral nucleosides, 5-alkenyl-1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)uracils. J. Med. Chem., 27, 91-94 (1984).
120. Witcher, J. W., Boudinot, F. D., Baldwin, B. H., Ascenzi, M. A., Tennant, B. C., Du, J. F. and Chu, C. K., Pharmacokinetics of 1-(2-fluoro-5-methyl-β-L-arabinofuranosyl) uracil (L-FMAU) in woodchucks. Antimicrob. Agents Chemother., 41, 2184-2187 (1997).
121. Wright, J. D., Ma, T.-W., Chu. C. K. and Boundinot, F. D., Pharmacokinetics of 1-(2-deoxy-2-fluoro-β-L-arabinofuranosyl)-5-methyluracil in rats. Pharm. Res., 12, 1350-1353 (1995).
122. Wright, J. D., Ma, T.-W., Chu, C. K. and Boudinot, F. D., Discontinuous oral absorption pharmacokinetic model and bioavailability of 1-(2-fluoro-5-methyl-β-L-arabinofuranosyl)-uracil (L-FMAU) in rats. Biopharm. and Drug Disposition, 17, 948, 1-11 (1996)
123. Wu, G. Y. and Wu, C. H., Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides. J. biol. Chem. 267, 12436-12439 (1992).
124. Wu, J., Sullivan, D. E. and Gerber, M. A., Quantitative polymerase chain reaction for the hepatitis B virus DNA. J. Virol. Methods, 49, 331-341 (1994).
125. Yokota, T., Konno, K., Chonan, E., Mochizuki, S., Kojima, K., Shigeta, S. and De Clerq, E., Comparative activities of several nucleoside analogues against duck hepatitis B virus in vitro. Antimicrob. Agents Chemother., 34, 1326-1330 (1990).
126. Yokota, T., Mochizuki, S., Konno, K., Mori, S., Shigeta, S. and De Clerq, E., Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis. Antimicrob. Agents Chemother., 35, 394-397 (1991).
127. Zoulim, F., Aguesse, S., Borel, C., Trepo, C. and Cheng, Y.-C., 2′-Fluoro-5-methyl-β-L-arabinofuranosyluracil, a novel L-nucleoside analogue, inhibits hepatitis B virus replication in primary hepatocytes and in vivo. Antiviral Res. 30, A24 (1996).
128. Zoulim, F., Dannaoui, E., Borel, C., Hantz, O., Lin, T.-S., Liu, S.-H., Trepo, C. and Cheng, Y.-C., 2′,3′-Dideoxy-β-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppress viral DNA synthesis in hepatocytes, both in vitro and in vivo. Antimicrob. Agents Chemother., 40, 448-453 (1996).